ReviewNucleic acid therapeutics2015
Combining CRISPR/Cas9 and rAAV Templates for Efficient Gene Editing.
Review in Nucleic acid therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Control of cell proliferation by memories of mitosis.Science (New York, N.Y.) · 2024Article
- Multi-omics profiling identifies a deregulated FUS-MAP1B axis in ALS/FTD-associated UBQLN2 mutants.Life science alliance · 2022Article
- A Cdk4/6-dependent phosphorylation gradient regulates the early to late G1 phase transition.Scientific reports · 2021Article
- CRISPR/Cas-Dependent and Nuclease-FreeHuman gene therapy · 2021Review
- Review
- Article
- Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- The classification, genetic diagnosis and modelling of monogenic autoinflammatory disorders.Clinical science (London, England : 1979) · 2018Review
- Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape.PLoS pathogens · 2016Review
- Stepping toward therapeutic CRISPR.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Protein kinase C fusion proteins are paradoxically loss of function in cancer.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Altering endogenous genes in cells is an integral tool of modern cell biology. The ease-of-use of the CRISPR/Cas9 system to introduce genomic DNA breaks at specific sites in vivo has led to its rapid and wide adoption. In the absence of a DNA template, the lesion is repaired by nonhomologous end joining resolving as internal deletions. However, in the presence of a homologous DNA template, homology-directed repair occurs with variable efficiencies. Recent work has demonstrated that highly efficient gene targeting can be induced by combining CRISPR/Cas9 targeting of genomic loci with recombinant adeno-associated virus (rAAV) to provide a single-stranded homologous DNA template. Here we review the current state of CRISPR/Cas-based gene editing and provide a practical guide to applying the CRISPR/Cas and rAAV system for highly efficient, time- and cost-effective gene targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.